Open access
Aug 2026
LKB1 Dysregulation in Duchenne Muscular Dystrophy Models: Disease Specificity and Epigenetic Control by HDAC Inhibitors
It is suggested that restoring LKB1 activity via HDAC inhibition or miRNA targeting may represent a therapeutic avenue to address dystrophic muscle dysfunction in Duchenne muscular dystrophy.
Brigida Boccanegra, Lisamaura Tulimiero, R. Quarta et al.
· Annals of the New York Acade... · 0 citations